OncologyOnline.net

Oncology Xagena

Xagena Mappa
Medical Meeting
Reumabase.it
XagenaNewsletter

Search results for "Squamous non-small cell lung cancer"

Researchers at the Ireland Cancer Center of University Hospitals of Cleveland have found a promising, novel biomarker that may be used to predict the survival of patients with advanced lung cancer and ...


The FDA ( Food and Drug Administration ) has expanded the approved use of Opdivo ( Nivolumab ) to treat patients with advanced ( metastatic ) squamous non-small cell lung cancer ( NSCLC ) with progres ...


Cancer Drugs Fund ( CDF ) Panel has assessed the application for single agent Pemetrexed ( Alimta ) to remain in the CDF as 2nd line treatment for patients with non-squamous ( NS ) non-small cell lun ...


Cancer Drugs Fund ( CDF ) Panel has assessed the application was for single agent Pemetrexed ( Alimta ) to remain in the CDF as maintenance treatment for patients with locally advanced or metastatic ...


Longer term ( 18 month ) survival data from CheckMate -057, an open-label, randomized phase 3 study evaluating Nivolumab [ Opdivo ] ( n=292 ) versus Docetaxel [ Taxotere ] ( n=290 ) in previously trea ...


Two-year overall survival data from two pivotal phase 3 studies evaluating Nivolumab ( Opdivo ) versus Docetaxel in previously treated metastatic non-small cell lung cancer ( NSCLC ) were announced. ...


The baseline serum cytokine levels of Platinum pretreated patients with advanced squamous non-small cell lung cancer ( NSCLC ) altered the efficacy of immunotherapy with Nivolumab ( Opdivo ), a fully ...


Updated results from Cohort G of the phase 2 KEYNOTE-021 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with Pemetrexed and Carboplatin ( Pem/Carbo ) in patients ...


The U.S. Food and Drug Administration ( FDA ) has approved an expanded label for Keytruda, an anti-PD-1 therapy, in combination with Pemetrexed ( Alimta ) and Platinum chemotherapy for the first-line ...


In KEYNOTE-189, Pembrolizumab ( Keytruda ) plus Pemetrexed ( Alimta ) and Platinum provided superior overall survival ( OS ) ( hazard ratio, HR 0.49, P less than 0.00001 ) and progression-free surviva ...


The first-line treatment with Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy has demonstrated improvements in overall survival ( OS ), progression-free survival ( P ...